Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing Exercise Capacity After PulseHaler™ Treatment in Chronic Obstructive Lung Disease (GOLD) II-IV of Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT04236076 is registered in ClinicalTrials.gov with Respinova LTD as lead sponsor.

NCT NCT04236076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04236076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing Exercise Capacity After PulseHaler™ Treatment in Chronic Obstructive Lung Disease (GOLD) II-IV of Chronic Obstructive Pulmonary Disease (COPD) Patients
Lead sponsor
Respinova LTD
Phase
Not applicable
Overall status
Unknown status
Start date
May 31, 2020
Completion date
June 30, 2021
Enrollment
104 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

copd